Topic: cancer-killing virus
The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
The takeover is focused on VSV candidates Boehringer sees becoming key components of its efforts to gain ground in the immuno-oncology sector.
Zika's ability to attack primitive nerve cells may also allow the virus to selectively target neuroblastoma cells.
A modified form of poliovirus seems to shrink breast tumors by latching onto a protein that's heavily expressed on the surface of some cancer cells.
Brazilian researchers are reporting promising results after testing a low concentration of purified Zika virus in mice with medulloblastoma and atypical teratoid rhabdoid tumor.
The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.
Combining oncolytic viruses with the MS drug Tecfidera could be an effective way to kill a range of cancers, including renal carcinoma, Canadian researchers discovered.
The deal gives AbbVie the chance to add Turnstone’s lead MAGEA3 candidate to its pipeline once data from two ongoing phase 1/2 trials are available.
New data from Amgen suggest adding an oncolytic virus could add even more punch to the treatment of melanoma.
Researchers at Duke University developing a glioblastoma treatment based on poliovirus are unraveling the process by which the virus fights malignancy.